Patient Global Impression of Change much or very much improved · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Patient Global Impression of Change much or very much improved · patients with fibromyalgia
Pregabalin leads to higher patient Global Impression of Change of 'much' or 'very much' improved compared with placebo at end of treatment (high certainty).
1 finding from 1 review
Patient Global Impression of Change much or very much improved · adults with moderate or severe pain associated with postherpetic neuralgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Patient Global Impression of Change much or very much improved · adults with moderate or severe pain associated with painful diabetic neuropathy
1 finding from 1 review
PGIC very much improved · adults with moderate or severe pain associated with painful diabetic neuropathy
1 finding from 1 review
Patient Global Impression of Change much or very much improved · adults with moderate or severe pain associated with painful diabetic neuropathy
1 finding from 1 review
Patient Global Impression of Change much or very much improved · adults with moderate or severe pain associated with postherpetic neuralgia
1 finding from 1 review
mg pregabalin · adults with moderate or severe neuropathic pain
2 findings from 1 review
no estimate extracted
300 participants
GRADE not reported
no estimate extracted
600 participants
GRADE not reported
At least 50% reduction in pain · adults with fibromyalgia
1 finding from 1 review
Adverse events as N of participants with at least one adverse event objective · adults with fibromyalgia enrolled in EERW studies
1 finding from 1 review
Serious adverse events · adults with fibromyalgia enrolled in EERW studies
1 finding from 1 review
Death · adults with fibromyalgia enrolled in EERW studies
1 finding from 1 review
PGIC very much improved · adults with fibromyalgia
1 finding from 1 review
At least 30% reduction in pain · adults with fibromyalgia
1 finding from 1 review
Moderate benefit · adults with fibromyalgia
1 finding from 1 review
Lack of efficacy withdrawal · adults with fibromyalgia
1 finding from 1 review
Withdrawals due to adverse events · adults with fibromyalgia
1 finding from 1 review
Serious adverse events · adults with fibromyalgia
1 finding from 1 review
Death · adults with fibromyalgia
1 finding from 1 review
Maintenance of initial therapeutic response of at least 30% pain intensity reduction over baseline and continued treatment at 13 or 26 weeks (equivalent to 'moderate benefit') · adults with fibromyalgia enrolled in EERW studies
1 finding from 1 review